
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type from the provided ranked marker list, I will follow the outlined steps to ensure a comprehensive analysis.<br><br>### Step 1: List the Key Functional Markers<br>- **SLC5A8**: A sodium-coupled monocarboxylate transporter involved in the transport of short-chain fatty acids and other monocarboxylates.<br>- **DCD (Dermcidin)**: An antimicrobial peptide with roles in innate immunity.<br>- **SERHL2**: A serine hydrolase-like protein, though its specific function is less characterized.<br>- **HIST1H3H, HIST1H2BN, HIST1H1C**: Histone proteins involved in chromatin structure and gene regulation.<br>- **G6PC3**: A glucose-6-phosphatase involved in glucose metabolism.<br>- **ALDH3B2, ALDH2**: Aldehyde dehydrogenases involved in detoxifying aldehydes and in retinoic acid biosynthesis.<br>- **ERBB2 (HER2/neu)**: A receptor tyrosine kinase involved in cell growth and differentiation, often overexpressed in breast cancer.<br>- **CRABP2**: Cellular retinoic acid-binding protein, involved in retinoic acid signaling.<br>- **RAC3**: A small GTPase involved in cell signaling and cytoskeletal organization.<br><br>### Step 2: List the Key Cell Type Markers<br>- **CD24**: A cell surface protein often used as a marker for breast cancer stem cells and other epithelial cells.<br>- **PODXL2**: Podocalyxin-like protein, associated with cell adhesion and migration.<br>- **CD164**: A sialomucin that plays a role in hematopoietic cell adhesion and migration.<br>- **ERBB2**: As mentioned, a key marker in breast cancer, particularly in HER2-positive subtypes.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on breast cancer, we can cross-reference these markers:<br>- **CD24** and **ERBB2** are strongly associated with breast epithelial cells and breast cancer subtypes.<br>- **CRABP2** and **ALDH2** are involved in retinoic acid metabolism, which is significant in epithelial cell differentiation and cancer.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of **CD24**, **ERBB2**, and other epithelial markers, the most probable general cell type is **epithelial cells**, specifically those associated with breast tissue.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **HER2-positive Breast Cancer Cells**: Due to the high expression of **ERBB2**.<br>2. **Luminal Epithelial Cells**: Given the presence of **CD24** and markers involved in retinoic acid signaling.<br>3. **Basal-like Breast Cancer Cells**: Although less likely, the presence of certain histone markers and **CD24** could suggest a basal-like phenotype.<br><br>The most likely subtype, based on the markers, is **HER2-positive Breast Cancer Cells** due to the prominent expression of **ERBB2**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of epithelial cells, with a strong indication towards HER2-positive breast cancer cells. This is supported by the high expression of **ERBB2**, along with other markers like **CD24** and **CRABP2**, which are associated with breast epithelial and cancer cell phenotypes.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    To validate the annotation result, let's follow the outlined steps:<br><br>### Step 1: Marker Consistency<br>- **Markers in the Provided List**: The markers used in the annotation (e.g., SLC5A8, DCD, SERHL2, HIST1H3H, CD24, ERBB2, etc.) are indeed present in the provided marker list.<br>- **Consistency with Identified Cell Type**: The markers used are consistent with the identified cell type. For example, **CD24** and **ERBB2** are well-known markers for breast epithelial cells and HER2-positive breast cancer cells, respectively. **CRABP2** and **ALDH2** are involved in retinoic acid metabolism, which is relevant to epithelial cell differentiation and cancer.<br><br>### Step 2: Mixed Cell Type Consideration<br>- **Potential Mixed Populations**: The annotation suggests a primary identification of HER2-positive breast cancer cells, with consideration for luminal epithelial cells and basal-like breast cancer cells. The presence of multiple high-ranking markers such as **CD24**, **ERBB2**, and histone proteins supports the possibility of mixed cell types. However, the analysis leans towards a dominant HER2-positive breast cancer cell type, which is reasonable given the marker expression.<br><br>### Conclusion<br>The annotation is consistent with the provided marker list and the identified cell type. The potential for mixed cell types has been acknowledged, but the primary identification is well-supported by the markers.<br><br>Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Epithelial Cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>HER2-positive Breast Cancer Cells</li><li>Luminal Epithelial Cells</li><li>Basal-like Breast Cancer Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">85</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a thorough analysis of the single-cell data, with a focus on identifying the most probable cell types based on the ranked marker list. The analysis correctly identifies key markers such as **ERBB2** and **CD24**, which are highly relevant to breast cancer and epithelial cells, respectively. The identification of HER2-positive breast cancer cells as the primary subtype is well-supported by the presence of **ERBB2**, a critical marker for this subtype.<br><br>The annotation process shows a balanced consideration of multiple markers, including those involved in retinoic acid metabolism (**CRABP2**, **ALDH2**) and histone proteins, which are relevant to chromatin structure and gene regulation. This indicates a comprehensive approach to understanding the cell populations present.<br><br>However, there are some areas for improvement. While the analysis acknowledges the potential for mixed cell types, it could have explored this aspect further, especially given the presence of markers like **CD24** and histone proteins, which might suggest a more diverse cell population. Additionally, the analysis could have placed more emphasis on the rank of the markers, as the order of appearance might indicate their relative importance in the dataset.<br><br>Overall, the annotation is scientifically accurate and provides a comprehensive view of the cell types present, with a strong focus on the most relevant markers. There are no obvious misclassifications, and the analysis captures the general picture of the cell populations effectively.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    